Quest Diagnostics Launches AD-Detect®: Innovative Blood Tests for Alzheimer’s Diagnosis
- Quest Diagnostics developed the AD-Detect® tests, improving Alzheimer’s diagnosis with high accuracy and reduced reliance on invasive procedures.
- The first AD-Detect® test launches in Q1 2026, evaluating biomarkers with a low indeterminate result rate of 10%.
- Quest Diagnostics' innovations align with patient needs and clinical guidelines, enhancing care for Alzheimer’s and other neurodegenerative diseases.
Quest Diagnostics Pioneers Blood-Based Alzheimer’s Tests, Enhancing Diagnostic Accuracy
Quest Diagnostics has made a significant advancement in Alzheimer’s disease diagnosis with the development of two blood-based tests known as AD-Detect®. These tests, which demonstrate high accuracy, are the result of a recent study published in Neurology® Clinical Practice, conducted in collaboration with the 1Florida Alzheimer’s Disease Research Center at the University of Florida. The findings suggest that these tests could substantially decrease the reliance on more invasive procedures such as PET imaging or cerebrospinal fluid analyses, marking a transformative shift in the diagnostic landscape for Alzheimer’s disease.
According to Dr. Michael Racke, Senior Medical Director of Neurology at Quest Diagnostics, the AD-Detect® tests can achieve an indeterminate result rate as low as 10%, which can significantly aid clinical decision-making for both healthcare providers and patients. The first test evaluates critical biomarkers, including amyloid beta (AB) 42/40, phosphorylated tau (p-tau) 217, and ApoE4 proteotype, with a planned launch set for Q1 2026. The second test, introduced earlier in April 2025, evaluates amyloid beta and p-tau217 without including ApoE4. Both tests have shown remarkable sensitivity and specificity of 91%, meeting the stringent standards set by the Alzheimer’s Association and the Global CEO Initiative on Alzheimer’s Disease for confirmatory tests.
The study, which encompassed 215 patients diagnosed with mild cognitive impairment or Alzheimer's disease, revealed that 46% of participants were amyloid PET-positive. This underscores the effectiveness of the AD-Detect® tests within the target population for which they are designed. With these innovations, Quest Diagnostics not only enhances diagnostic accuracy but also aligns its offerings with evolving clinical guidelines and patient needs, potentially improving overall patient care in the realm of neurodegenerative diseases.
In addition to these advancements, the introduction of blood-based testing for Alzheimer’s represents a broader trend in the healthcare industry towards less invasive diagnostic methods. As the demand for accessible and accurate diagnostic tools continues to rise, the implications of these tests extend beyond Alzheimer’s, potentially influencing the development of similar methodologies for other neurodegenerative conditions.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

